FLAG regimen in the treatment of refractory reducing acute myeloid leukemia aged 30 cases

Objective: To investigate the reduction of Ara-C in the FLAG regimen in the treatment of refractory acute myeloid leukemia(AML) in elderly efficacy and adverse reactions. Methods: In this study, FLAG cytarabine reduction programs, fludarabine 150 mg, intravenous infusion, 30 min after dropping the first 1 to 5 days; Ara-C 150 mg/m2, intravenous infusion, the first 1 to 5 days; G-CSF starting 1 d before the application of chemotherapy until the end of chemotherapy. 30 patients with refractory acute myeloid leukemia. Results: 30 patients, 13 patients with refractory acute myeloid leukemia achieved complete remission (CR rate was 43.3%), 6 cases of partial remission (PR rate was 20.0%), the total effective rate was 63.3%, invalid 7 cases, 4 deaths. Ara′s FLAG reduction program′s main adverse reactions were myelosuppression, gastrointestinal symptoms, mild liver damage and so on. Conclusion: The reduction of the FLAG program Ara-C in refractory acute myeloid leukemia relatively high response rate, adverse reactions can be accepted.